Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Curis Inc CRIS

Healthcare Biotechnology
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CRIS)

Curis Provides Updated Data from its Frontline AML Triplet Study

PR Newswire December 9, 2025

Curis to Present at Upcoming 30th Annual SNO Meeting

PR Newswire November 14, 2025

Curis Provides Third Quarter 2025 Business Update

PR Newswire November 6, 2025

Curis to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on November 6, 2025

PR Newswire October 30, 2025

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire October 3, 2025

Curis to Present at Upcoming Healthcare Conferences in September

PR Newswire September 2, 2025

Curis Provides Second Quarter 2025 Business Update

PR Newswire August 5, 2025

Curis to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2025

PR Newswire July 29, 2025

Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement

PR Newswire July 2, 2025
View More News ››

Opinion & Analysis (NDAQ:CRIS)

Curis' Shares Take Off as FDA Clears IND Application for Monoclonal Anti-VISTA Antibody

Streetwise Reports June 11, 2020
View More Opinion ››

Bullboard Posts (NDAQ:CRIS)

Curis Inc (NASDAQ:CRIS): A Biotech Focused on Innovative Can

Emavusertib looks promising. CRIS showing some interesting data in leukemia and lymphoma trials. 4/10 patients in lymphoma study got...
MikeTester - January 24, 2025

Buy buddy buy.

It's time for this stock to start climbing up today,so good luck to all of us shareholders out there.
coolfooldumbguy - January 2, 2025

Curis (NASDAQ:CRIS) Reports Promising Progress in Advancing

http://beyondspx.com/2024/08/02/curis-nasdaqcris-reports-promising-progress-in-advancing-emavusertib-across-key-hematological...
MikeTester - August 3, 2024

should be a good year here

for this stock,so glta.
coolfooldumbguy - March 31, 2019

it's a buy today for me

it looks like it will perform this year,so glta.
coolfooldumbguy - March 25, 2019

STELLAR RESULTS!

Curis Reports First Quarter 2016 Financial Results CRIS | 49 minutes ago  ...
Interpolation1 - May 9, 2016
View more Bullboard ››

Vanstar Mining Resources Inc.

Vanstar Mining Resources Inc.

Vanstar Mining’s Nelligan gold project joint venture with IAMGOLD (25% VSR/75% IMG), located 60 kilometres SW of Chibougamau, ...
View More »

Podcasts